Interlinked
Interlinked AB is a Swedish medical device
Company name
Interlinked AB
When was the company founded?
2016
Do you have any academic affiliations or collaborations?
Yes. Interlinked AB was founded in 2016 as a spin-off from the Clinical Innovation Fellowships (CIF) program. The program is designed to bring together multidisciplinary talent from engineering, medicine, business and design to identify unmet clinical needs and translate them into practical, scalable and commercially relevant healthcare solutions.
The program is supported by EIT Health and leading organisations such as RISE, KTH Royal Institute of Technology and Karolinska Institutet.
Describe your company
Interlinked AB is a Swedish medical device company focused on improving patient safety through practical innovation. Founded in 2016 as a spin-off from the Clinical Innovation Fellowships (CIF) program, part of EIT Health, the company develops smart, connected medical technologies that help make healthcare safer and more efficient.
Interlinked has grown from a research project into a commercial company with a validated product platform, strong regulatory groundwork and scalable manufacturing. The company is now preparing for full commercial launch, expanding its pipeline and building long-term value for patients, healthcare providers and investors.
Describe your product/solution
ReLink features a self-sealing double-valve system that reduces spillage of medicine and fluids. Unlike other breakaway connectors, both ReLink valves use a split-septum design, allowing for disinfection (“scrub the hub”) and reconnection. With ReLink, no device replacement is needed before therapy restart, meaning the system remains closed at all times. A closed system helps protect patients from air and contaminants while reducing exposure risks for healthcare staff.
ReLink IV is approved for dual use and tailored for both military and civilian IV settings. Its ease of use makes it suitable for frontline field hospitals and disaster relief environments.
What problem are you addressing?
Catheter dislodgement is a persistent and under-recognised source of patient harm. Dislodgement can occur in any setting, from routine ward care to emergency and pre-hospital environments, leading to wasted medication, infection risk, extended hospital stays and increased workload for already strained healthcare staff.
What impact does your solution create?
ReLink offers a substantial reduction in the risk of dislodgement while mitigating the consequences when incidents occur. The platform strengthens the infusion system through a reconnectable breakaway connector approach that helps reduce therapy interruptions and fluid leakage.
Unlike other breakaway connectors, both ReLink valves use a split-septum design, allowing for disinfection and reconnection without replacing the device. This helps maintain a closed system throughout therapy.
Designed as a scalable platform, ReLink can be extended across civilian, military and veterinary care, as well as broader fluid management applications. The platform supports use in hospital, field and home-care settings for both human and animal care.
The platform is supported by clinical and investigational data across human, drainage and veterinary use cases, helping lower adoption risk by providing evidence that ReLink can improve line resilience and treatment continuity in real-world care settings.
Clinical and investigational studies include:
- A randomized controlled trial of ReLink IV at a Swedish university hospital demonstrating a 73% reduction in peripheral IV catheter dislodgement
- An investigational study of ReLink Veterinary at a Swedish university animal hospital showing a 64% reduction in IV catheter dislodgement in dogs
- A pilot study of ReLink Drain at an Irish university hospital indicating an 83% reduction in dislodged drains
What stage of commercialisation are you currently in?
Interlinked is currently in an early market scaling phase.
What are you currently seeking to take the next step?
2026 is a crucial year for driving adoption of ReLink and establishing the foundation for future sales growth. The company is currently seeking funding of EUR 4 million.
What market potential do you see for your solution?
Globally, more than 16 billion IV lines are used annually, alongside a significant drainage market of approximately 1.35 million catheters. ReLink addresses this large and growing market in IV therapy and drainage, where line failure, leakage and interruption create significant clinical and economic challenges.
ReLink is differentiated by addressing the problem at a system level. Its reconnectable, valved breakaway design is intended not only to reduce the consequences of accidental dislodgement, but also to enable rapid reinstatement of therapy while maintaining a closed system. This positions ReLink as a broader safety and workflow solution rather than a conventional securement product or single-use breakaway connector.
The company’s go-to-market strategy focuses on markets where approval can be rapidly translated into revenue. In Europe, ReLink IV and ReLink Drain already hold CE approval, making the EU the first wave for commercial rollout. Initial focus markets include Italy, Greece and Malta, where distributor agreements are already in place, while also building expansion into larger European markets such as Germany, France, Sweden, Scandinavia and the Benelux region.
In parallel, the U.S. market represents an important opportunity for early revenue generation through the Drain and Veterinary segments, both of which are already marketed through local partners.
Website;
https://www.interlinked.care/
Contact:
Aneek Lal
CFO
aneek.lal@interlinked.care
